Nosocomial pneumonia: Aetiology, diagnosis and treatment

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 3, 2006, Pages 192-197

  Depuydt, Pieter ^a   Myny, Dries ^a   Blot, Stijn ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Early appropriate therapy; Invasive diagnosis; Multidrug resistance; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG EXPOSURE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; META ANALYSIS; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRESCRIPTION; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; BACTERIAL PNEUMONIA; CROSS INFECTION; DIFFERENTIAL DIAGNOSIS; PROGNOSIS;

ANTI-INFECTIVE AGENTS; CROSS INFECTION; DIAGNOSIS, DIFFERENTIAL; HUMANS; PNEUMONIA; PNEUMONIA, BACTERIAL; PROGNOSIS;

EID: 33745052401     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000219268.35063.b0     Document Type: Review

References (70)

1. Finkelstein R, Rabino G, Kassis I, et al. Device-associated, device-day infection rates in an Israeli adult general intensive care unit. J Hosp Infect 2000; 44:200-205.
2. Johanson WG, Pierce AK, Sanford JP, et al. Nosocomial respiratory infection with Gram-negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 1972; 77:701-706.
3. Cavalcanti M, Valencia M, Torres A. Respiratory nosocomial infections in the medical intensive care unit. Microbes Infect 2005; 7:292-301. Review of epidemiology, pathogenesis, risk factors and treatment of ICU-acquired respiratory infections.
4. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995; 274:639-644.
5. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416. The 2005 update of the joint American Thoracic Society and Infectious Diseases Society of America endorsed guidelines offers an evidence-based review of the epidemiology, pathogenesis, prevention and treatment of nosocomial pneumonia.
6. Myny D, Depuydt P, Colardyn F, et al. Ventilator-associated pneumonia in a tertiary care ICU: analysis of risk factors for acquisition and mortality. Acta Clin Belg 2005; 60:114-121. In this single centre study, the majority of VAP cases occurred in the first week following mechanical ventilation. After correcting for severity-of-illness, VAP was not associated with increased mortality.
7. Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 57:1165-1172.
8. Antonelli M, Moro ML, Capelli O, et al. Risk factors for early-onset pneumonia in trauma patients. Chest 1994; 105:224-228.
9. Gastmeier P, Sohr D, Geffers C, et al. Mortality in German intensive care units: Dying from or with a nosocomial infection. Anasthesiol Intensivmed Not-fallmed Schmerzther 2005; 40:267-272. This study focused on mortality of nosocomial pneumonia and blood stream infection, based on data from German ICUs from the period 1997-2004.
10. Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 26:538-542.
11. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-1987. This matched cohort analysis identified a 23% excess mortality in patients with VAP caused by methicillin resistant Staphylococcus aureus as compared to patients without pneumonia, despite treatment with glycopeptides.
12. Bauer TT, Valencia M, Badia JR, et al. Respiratory microbiology patterns within the first 24 h of ARDS diagnosis: influence on outcome. Chest 2005; 128:273-279. This study described the incidence and pattern of airway colonization within 24 h of diagnosis of ARDS. Neither isolation of pathogenic microorganisms nor a diagnosis of nosocomial pneumonia affected mortality in univariate analysis.
13. Nseir S, Di Pompeo C, Soubrier S, et al. Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005; 128:1650-1656. VAP was identified as the only independent risk factor for mortality in a prospective, matched cohort analysis of chronic obstructive pulmonary disease patients requiring intubation. Interestingly, corticosteroid use in these chronic obstructive pulmonary disease patients with VAP was associated with a lower mortality and a shorter duration of ventilation.
14. Rosenthal VD, Guzman S, Migone O, et al. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: A prospective, matched analysis. Am J Infect Control 2005; 33:157-161. Matched cohort analysis estimating a 30% attributable mortality and an 8.9-day mean extra length of stay for VAP.
15. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-1317.
16. Hugonnet S, Eggiman P, Borst F, et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004; 25:1090-1096. This retrospective matched cohort analysis found an attributable extra hospital stay of 10 days and an attributable cost of US$15 986 per episode of VAP.
17. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539.
18. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649-655. This was a retrospective study of risk factors for acquisition and for mortality in VAP caused by Acinetobacter baumannii.
19. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48:224-228.
20. Depuydt PO, Blot SI, Benoit DD, et al. Antimicrobial resistance in nosocomial blood stream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med (in press).
21. El-Solh AA, Pietrantoni C, Bhat A, et al. Indicators of potentially drug-resistant bacteria in severe nursing home acquired pneumonia. Clin Infect Dis 2004; 39:474-480. A binary partitioning risk assessment for multi-drug resistance cause was developed from a derivation cohort of 88 subjects with nursing-home pneumonia, and validated in 47 patients. No MDR organisms were present if patients received no prior antibiotics and were independent (Activity of Daily living Lower than cut-off of 12.5). In the presence of both risk factors (prior antibiotics and Activity of Daily Living > 12.5), risk for MDR was 90%.
22. Apfalter P, Stoiser B, Baroush W, et al. Community-acquired bacteria frequently detected by means of quantitative polymerase chain reaction in nosocomial early-onset ventilator-associated pneumonia. Crit Care Med 2005; 33:1492-1498. In 25 of 100 patients with early VAP but a prior hospital stay of 14 days, a quantitative polymerase chain reaction tool identified S. pneumoniae, M. pneumoniae, or C. Pneumoniae. In 71% of these, conventional culture yielded no significant growth.
23. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and lateonset ventilator-associated pneumonia are caused mainly by potentially multi-resistant bacteria. Intensive Care Med 2005; Sep 7 [Epub ahead of print]. Staphylococcus aureus and Pseudomonas aeruginosa were the most common isolated organisms both in early (< 7 days) and late (≥ 7 days) VAP in a Greek university hospital ICU.
24. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant Gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005; 40:1792-1798. This paper describes the increasing isolation of multidrug-resistant Gram-negative bacilli, Escherichia coli, Enterobacter cloacae and Klebsiella species in patients at hospital admission. Risk factors for MDR were age > 65 years, prior antibiotic exposure and residence in a long-term care facility.
25. Seenivasan MH, Yu VL, Muder R. Legionnaires' disease in long-term care facilities: Overview and proposed solutions. J Am Geriatr Soc 2005; 53:875-880. This is a review dealing with the role of Legionella in nursing home patients' pneumonia. The authors argue that Legionella is a frequent but underrecognized cause of pneumonia in these patients and recommend both regular sampling of the potable water system for the organism and more widespread use of the rapid urinary antigen test in long-term care facilities.
26. Daubin C, Vincent S, Vabret A, et al. Nosocomial viral ventilator-associated pneumonia in the intensive care unit: a prospective cohort study. Intensive Care Med 2005; 31:1116-1122. This prospective study in > 48-h ventilated patients conducted over a 9-month period found HSV-1 infection in 30% of VAP patients. Beside this, no causative viral pathogen was found in VAP patients.
27. Bruynseels P, Jorens PG, Demey HE, et al. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet 2003; 362:1536-1541.
28. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: Associated factors and consequences. Chest 2005; 127:233-241. In ICU patients with prolonged fever without evidence for bacterial or fungal disease, cytomegalovirus antigenemia was present in 17%.
29. Leung AY, Chan M, Cheng VC, et al. Quantification of adenovirus in the lower respiratory tract of patients without clinical adenovirus-related respiratory disease. Clin Infect Dis 2005; 40:1541-1544.
30. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170:621-625. This study described 127 cases of invasive aspergillosis in a medical ICU population, 77% of whom had no underlying hematological illness. Mortality was 80%. Five patients with histologically proven aspergillosis had none of the classical risk factors: three of these patients had Child C liver cirrhosis.
31. Vandewoude K, Blot S, Benoit D, et al. Invasive aspergillosis in critically ill patients: Analysis of risk factors for acquisition and mortality. Acta Clin Belg 2004; 59:251-257. Twenty-one of 38 ICU patients with invasive aspergillosis had no classical risk factors for the disease. Mortality in these patients was gravely affected by aspergillus, as illustrated by an observed mortality in excess of APACHE II predicted mortality.
32. El-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients: an immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156:583-590.
33. Eggimann P, Garbino J, Pittet D. Management of candida species infections in critically ill patients. Lancet Infect Dis 2003; 3:772-785.
34. Azoulay E, Cohen Y, Zahar JR, et al. Practices in non-neutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med 2004; 30:1384-1389. A questionnaire study in French ICUs revealed wide variation in diagnosis of Candida pneumonia, and in initiation of antifungal therapy upon isolation of Candida from the respiratory tract.
35. Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385-1392. This describes a large (71) series of pulmonary autopsy findings in bone marrow transplant patients.
36. Terpenning M. Geriatric oral health and pneumonia risk. Clin Infect Dis 2005; 40:1807-1810. The concise review focuses on the role of oral hygiene in aspiration pneumonia in the elderly.
37. El-Solh AA, Pietrantoni C, Bhat A, et al. Colonization of dental plaques: A reservoir of respiratory pathogens for hospital acquired pneumonia in institutionalized elders. Chest 2004; 126:1575-1582. Respiratory pathogens recovered from the protected broncho-alveolar lavage fluid in patients with VAP were compared genetically with those isolated from dental plaque by pulsed-field gel electrophoresis.
38. Fourrier F, Dubois D, Pronnier P, et al. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: A double-blind placebo-controlled multicenter study. Crit Care Med 2005; 33:1728-1735. Gingival antiseptic decontamination in intubated patients could not reduce incidence of VAP in this study in six ICUs.
39. Valles J, Mariscal D, Cortes P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004; 30:1768-1775.
40. Grundmann H, Barwolff S, Tami A, et al. How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 2005; 33:946-951. Genetic typing of the 10 bacterial species most frequently associated with ICU-acquired nosocomial infection was performed on all clinical and surveillance isolates during a period of 18 months. Forty-one of 278 ICU-acquired infections (14.5%) could be associated with transmissions between patients
41. Meyer E, Ebner W, Heininger A, et al. Microbiological diagnostic and antibiotic rmanagement of community acquired and nosocomial pneumonias in intensive care units in Germany. Data from project SARI: Surveillance of antibiotic use and bacterial resistance in intensive care units. Anasthesiol Intensivmed Notfallmed Schmerzther 2005; 40:85-90. This study presented results of a questionnaire sent to German ICUs in 2000. Wide variations in diagnostics and empiric antibiotic choices were observed.
42. L'Hériteau F, Alberti C, Cohen Y, et al. Nosocomial infection and multidrug-resistant bacteria surveillance in intensive care units: A survey in France. Infect Control Hosp Epidemiol 2005; 26:13-20.
43. Boots RJ, Lipman J, Bellomo R, et al. The spectrum of practice in the diagnosis and management of pneumonia in patients requiring mechanical ventilation. Australian and New Zealand practice in intensive care (ANZPIC II) Anaesth Intensive Care 2005; 33:87-100.
44. Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med 2004; 30:844-852.
45. Schurink CA, Nieuwenhoven CA, Jacobs JA, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med 2004; 30:217-224. This study compared Clinical Pulmonary Infection Score (CPIS) with quantitative microbiological cultures of patients with suspected VAP. CPIS had low sensitivity and specificity for diagnosing VAP when compared to quantitative microbiological culture as a gold standard. Interobserver variability of the CPIS was large.
46. 4 CFU/ml. None of the patients had clinical signs of pneumonia.
47. Camargo LF, De Marco FV, Barbas CS, et al. Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates. Critical Care 2004; 8:R422-R430. In this prospective study in ventilated patients, sensitivity of quantitative and qualitative cultures for diagnosis of VAP were compared. Sensitivity was determined against a standard of a clinicoradiological diagnosis by a panel of three independent specialists.
48. Croce MA, Fabian TC, Mueller EW, et al. The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma 2004; 56:931-934. This retrospective study examined BAL results of 526 trauma patients with suspected VAP. A false-negative BAL was defined as any patient who had under 10(-5) colonies/ml and developed VAP with the same organism up to 7 days after the previous culture. Most false negative BALs occurred with Pseudomonas and Acinetobacter.
49. Zedtwitz-Liebenstein A, Schenk P, Apfalter P, et al. Ventilator- associated pneumonia: Increased bacterial counts in bronchoalveolar lavage by using urea as an endogenous marker of dilution. Crit Care Med 2005; 33:756-759. A great variation in dilution of BAL fluid was observed in this prospective study.
50. Butler KL, Best IM, Oster RA, et al. Is bilateral protected specimen brush sampling necessary for the accurate diagnosis of ventilator-associated pneumonia? J Trauma 2004; 57:316-322.
51. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. Crit Care Med 2005; 33:46-53. In this meta-analysis of randomized, controlled trials (RCT) of invasive diagnostic strategies in suspected ventilator-associated pneumonia and a separate pooled analysis of prospective, observational studies of the effect of invasive cultures on antibiotic utilization in ventilator-associated pneumonia only four RCT were with-held for analysis. The authors concluded that invasive strategies affected antibiotic use, but did not alter outcome.
52. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350:451-458. This was a prospective study of the value of a rapid immunoblot assay for soluble triggering receptor expressed on myeloid cells (s-TREM) in diagnosis of pneumonia (both nosocomial and community-acquired) in ventilated patients. Sensitivity and specificity of s-TREM, as compared to a post hoc diagnosis of pneumonia as gold standard, were 98 and 90% respectively.
53. Hugues G, Leroy O, Guéry B, et al. Soluble TREM-1 and the diagnosis of pneumonia. N Engl J Med 2004; 350:1904-1905.
54. Blot S, Vandewoude K. Early detection of systemic infection. Acta Clin Belg 2004; 59:20-23.
55. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155.
56. Vincent JL. Nosocomial infections in adult intensive care units. Lancet 2003; 361:2068-2077.
57. Hernandez G, Rico P, Diaz E, et al. Nosocomial lung infections in adult intensive care units. Microbes Infect 2004; 6:1004-1014.
58. Mehrota R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30:2145-2156. This is a review of pharmacokinetics and pharmacodynamics of antimicrobial agents in critically ill patients. Critical illness can greatly alter pharmacokinetic of antibiotics especially due to increases in distribution volume.
59. Gillespie EL, Kuti JL, Nicolau DP. When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn Med 2005; 69:203-210.
60. Ramphal R. Importance of adequate initial antibiotic therapy. Chemotherapy 2005; 51:171-176. The review is based on a PubMed search from 1997 to 2004 focusing on papers dealing with appropriate therapy.
61. Brun-Buisson C, Fartoukh M, Lechapt E, et al. Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia. Chest 2005; 128:533-544. This prospective study focused on the impact of immediate microbiological processing of blind and directed protected aspiration on adequacy of early antibiotic therapy.
62. Davis KA, Eckert MJ, Lawrence R, et al. Ventilator-associated pneumonia in injured patients: do you trust your Gram's stain? J Trauma 2005; 58:462-467. This retrospective study focused on microbiologically proven VAP in trauma patients. Overall accuracy of Gram's stain was 88%, but accuracy declined to 63% and 72% for predicting specific cause in Gram-negative and Gram-positive pneumonia respectively.
63. Leroy O, d'Escrivan T, Devos P, et al. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005; 33:129-135. This observational study included 168 patients with hospital-acquired pneumonia. Imipenem resistance was observed in 25%. Imipenem resistance was associated with prior use of fluoroquinolones, aminoglycoside and severity of pneumonia, as expressed by the need for invasive monitoring and the presence of bilateral infiltrates on chest radiograph.
64. Michel F, Francescini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: A role for routine endotracheal aspirate cultures. Chest 2005; 127:589-597. Thirty-four of 41 cases of VAP proven by BAL culture had a prior endotracheal aspirate growing the same organism. In this study, surveillance endotracheal aspirate cultures were performed twice weekly in all ventilated patients. Antibiotic prescription based on this surveillance was more adequate than a hypothetical prescription based on clinical factors.
65. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183-2190. This was a study of the feasibility of a de-escalation approach in a single ICU.
66. Colardyn F. Appropriate and timely empirical antimicrobial treatment of ICU infections: a role for carbapenems. Acta Clin Belg 2005; 60:51-62. This is a review of the concept or early appropriate antimicrobial therapy in ICU-acquired infection.
67. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799. This prospective trial randomized patients with VAP for having duration of antibiotic therapy determined by a formal antibiotic discontinuation guideline or by clinical decision by the treating physician. Overall duration of antibiotic treatment was reduced in the guideline arm: median duration was 6 versus 8 days in the conventional arm.
68. Vidaur L, Gualis B, Rodriguez A, et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med 2005; 33:1248-1253. This was a prospective study on the evolution of clinical factors during the course of VAP in patients with and without ARDS.
69. Povoa R, Coelho L, Almeida A, et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J 2005; 25:804-812. Serial CRP analyses in 47 patients with VAP were used to predict outcome. A CRP of >0.6 times the initial level on day 4 was predictive of a poor outcome with a sensitivity of 0.92 and a specificity of 0.59. On the other hand, both a fast (identified as a <0.4 decrease of CRP on day 4 as compared to day 0) and a slow but continuous decrease in CRP levels were associated with survival.
70. Luyt CE, Guérin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48-53. Procalcitonin kinetics predicted outcome in this prospective observational study of 63 patients with VAP.